

CLAIMS

1. An isolated crystalline form 16 of 2-methyl-1-[(4-[6- (trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl] amino}-1,3,5-triazin-2- yl)amino]propan-2-ol, characterized by an X-ray powder diffraction pattern having peaks at 2θ angles of 6.8, 10.6, 13.6, 14.2, and $19.2^\circ \pm 0.2^\circ$.
2. The isolated crystalline form of claim 1, characterized by an X-ray powder diffraction pattern substantially similar to FIGURE 34.
3. Use of the crystalline form of claim 1 or 2 for manufacture of a medicament for treating an advanced hematologic malignancy selected from acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), myeloid sarcoma, multiple myeloma, and lymphoma, each characterized by the presence of a mutant allele of IDH2.
4. The use of claim 3, wherein the advanced hematologic malignancy is acute myelogenous leukemia (AML).
5. The use of any of claim 4, wherein the advanced hematologic malignancy is relapsed or primary refractory acute myelogenous leukemia.
6. The use of any one of claims 3-5, wherein the medicament is to be administered as a first line, second line, third line, or fourth line treatment for acute myelogenous leukemia.
7. A pharmaceutical composition comprising the isolated crystalline form of claim 1 or 2 and a pharmaceutically acceptable carrier.